A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease

NCT07120152 | Not Yet Recruiting FDA Drug

• 1 other identifier: G-2024-8508-R2(AMD)
• Study Type: observational
• Target: 439
• Locations: 0 countries
• Sites: N/A

Brief Summary

A subcutaneous formulation of infliximab CT-P13 (Remsima, Celltrion) has been approved for clinical use in inflammatory bowel disease (IBD) and rheumatoid arthritis (RA) after demonstration of pharmacokinetic (PK) non-inferiority compared to intravenous CT-P13. The added value of the subcutaneous formulation of CT-P13 has been recognized by IBD physician expert, patients and nurses. However, further investigation is needed to select the right patients and timing for switching to the new subcutaneous formulation. Before investing resources into the design and execution of a prospective clinical trial to address these remaining clinical questions and concerns, an in silica simulation study using a population pharmacokinetic-pharmacodynamic (popPK-PD) model of CT-P13 would be highly informative. While popPK models of subcutaneous infliximab CT-P13 have been developed for both IBD and RA, a popPK-PD model is still awaited. The development of a popPK-PD model would allow us to bridge infliximab exposure and response, and address clinically relevant questions by focussing on therapeutic outcomes.

Conditions

IBD - Inflammatory Bowel Disease; RA - Rheumatoid Arthritis

Keywords

pharmacokinetic-pharmacodynamic model; Model; IBD; Inflammatory Bowel Disease; Infliximab

Outcome Measures

Primary Outcomes (1)

• Dose-exposure-response relationship of subcutaneous infliximab

  To understand, describe, and predict the dose-exposure relationship of sibcutaneous infliximab in patients with inflammatory bowel diseased based on available data from previous clinical trials.

  At least 24 weeks

Study Arms (1)

Patients with IBD

Patients who have active Crohn's disease with a score on the Crohn's disease activity index between 220 and 450 points. Or patient has active Ulcerative colitis defined by a total Mayo score between 6 and 12 points (part 2 only).

Drug: Subcutaneous infliximab CT-P13 Remsima®SC

Interventions

Subcutaneous infliximab CT-P13 Remsima®SC DRUG

Subcutaneous infliximab

Patients with IBD

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients with inflammatory bowel disease

You may qualify if:

• Patients with Crohns disease with a score on the Crohn's disease activity index between 220 and 450.
• Patients with active Ulcerative colitis as defined by a total Mayo score between 6 and 12 points (Part 2 only)

You may not qualify if:

• Patients who have previously received a biological agent for the treatment of CD and UC and/or a tumor necrosis factor-alpha (TNFa)-inhibitor for the treatment of other diseases.
• Patients who have allergies to any of the excipients of infliximab or any other murine and/or human proteins or patients with a hypersensitivity to immunoglobulin products.
• Patients who have a current or past history of infection with HIV, hepatitis B or C (carriers of hepatitis B and C are not permitted to enrol into the study, but past hepatitis B resolved can be enrolled).
• Patients who have acute infections requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of the study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug.
• Patient who have an indeterminate result for interferon-y release assay (IGRA) or latent tuberculosis (TB) at Screening. For part 2, if IGRA result is indeterminate at the Screening, one retest will be possible during the screening. If the repeated IGRA result is negative, the patient can be included in the study.

Sponsors & Collaborators

• Erwin Dreesen: lead
• San Raffaele University Hospital, Italy: collaborator
• University of Liverpool: collaborator
• Hospital Universitario La Fe: collaborator
• University of Southampton: collaborator
• Samsung Medical Center: collaborator

Related Links

• Related Info
• Related Info

MeSH Terms

Conditions

Inflammatory Bowel Diseases; Arthritis, Rheumatoid

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Skin and Connective Tissue Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Erwin Dreesen, Prof. Dr.

CONTACT

+32 16 37 27 53; erwin.dreesen@kuleuven.be

Vicky Steyfkens, MSc

CONTACT

+32 16 37 26 25; vicky.steyfkens@kuleuven.be

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: August 6, 2025
• First Posted: August 13, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): March 1, 2027
• Last Updated: September 3, 2025

Record last verified: 2025-08